Richard has garnered extensive experience leading commercial projects, ranging from commercial opportunity assessments, launch strategy, demand forecasting, segmentation, claims data analysis, to commercialization strategy.
He drives analytically driven strategic recommendations to leading pharmaceutical and biotechnology clients across the globe, with expertise in a wide range of therapeutic areas including oncology, hematology, infectious diseases, and rare diseases.
Richard earned his BA in Biology & Society with minors in Business Management and Nutritional Sciences at Cornell University in 2017. He recently completed his MBA degree from London Business School in 2024.